Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.
1. A composition comprising (a) a first antibody and a second antibody, wherein the first antibody comprises a first antigen-binding region capable of binding to human CD37 and a first Fc region of a human IgG, and the second antibody comprises a second antigen-binding region capable of binding to human CD20 and a second Fc region of a human IgG, wherein both the first Fc region and the second Fc region comprise a substitution of an amino acid at a position corresponding to E430, E345 or S440 in human IgG1 when using the EU numbering system, with the proviso that the substitution in S440, if present, is S440Y or S440W, and (b) a carrier,
wherein the first antigen-binding region comprises a variable heavy chain (VH) region comprising CDR sequences HCDR1, HCDR2 and HCDR3 and a variable light chain (VL) region comprising CDR sequences LCDR1, LCDR2 and LCDR3 selected from the group consisting of:
a. SEQ ID NOs: 22, 23, and 24, respectively, and SEQ ID NO: 26, the sequence EAS, and SEQ ID NO: 27, respectively,
b. SEQ ID NOs: 29, 30, and 31, respectively, and SEQ ID NO: 33, the sequence AAS, and SEQ ID NO: 34, respectively,
c. SEQ ID NOs: 36, 37, and 38, respectively, and SEQ ID NO: 40, the sequence KAS, and SEQ ID NO: 41, respectively,
d. SEQ ID NOs: 43, 44, and 45, respectively, and SEQ ID NO: 47, the sequence YAS, and SEQ ID NO: 48, respectively,
e. SEQ ID NOs: 43, 44, and 45, respectively, and SEQ ID NO: 47, the sequence YAS, and SEQ ID NO: 58, respectively,
f. SEQ ID NOs: 8, 9, and 10, respectively, and SEQ ID NO: 12, the sequence VAT, and SEQ ID NO: 13, respectively, and
g. SEQ ID NOs: 15, 16, and 17, respectively, and SEQ ID NO: 19, the sequence FAK, and SEQ ID NO: 20, respectively.
2. The composition according to claim 1 , wherein the first Fc region and the second Fc region comprise a substitution selected from the group consisting of: E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W.
3. The composition according to claim 1 , wherein the first Fc region further comprises a K439E substitution and the second Fc region further comprises an S440K substitution, with the proviso that the second Fc region does not comprise a S440Y or S440W substitution.
4. The composition according to claim 1 , wherein the first Fc region further comprises a S440K substitution and the second Fc region further comprises an K439E substitution, with the proviso that the first Fc region does not comprise a S440Y or S440W substitution.
5. The composition according to claim 1 , wherein the first antigen-binding region comprises VH and VL region sequences selected from the group consisting of:
a. SEQ ID NO: 49 and SEQ ID NO: 50, respectively,
b. SEQ ID NO: 51 and SEQ ID NO: 52, respectively,
c. SEQ ID NO: 53 and SEQ ID NO: 54, respectively,
d. SEQ ID NO: 55 and SEQ ID NO: 56, respectively,
e. SEQ ID NO: 55 and SEQ ID NO: 57, respectively,
f. SEQ ID NO: 7 and SEQ ID NO: 11, respectively, and
g. SEQ ID NO: 14 and SEQ ID NO: 18, respectively.
6. The composition according to claim 1 , wherein the second antigen-binding region comprises a VH region comprising CDR sequences HCDR1, HCDR2 and HCDR3, and a VL region comprising CDR sequences LCDR1, LCDR2 and LCDR3, selected from the group consisting of:
a. SEQ ID NOs: 60, 61, and 62, respectively, and SEQ ID NO: 64, the sequence DAS, and SEQ ID NO: 65, respectively,
b. SEQ ID NOs: 67, 68, and 69, respectively, and SEQ ID NO: 64, the sequence DAS, and SEQ ID NO: 71, respectively,
c. SEQ ID NOs: 73, 74, and 62, respectively, and SEQ ID NO: 64, the sequence DAS, and SEQ ID NO: 65, respectively,
d. SEQ ID NOs: 76, 77, and 78, respectively, and SEQ ID NO: 80, the sequence ATS, and SEQ ID NO: 81, respectively, and
e. SEQ ID NOs: 83, 84, and 85, respectively, and SEQ ID NO: 87, the sequence QMS, and SEQ ID NO: 88, respectively.
7. The composition according to claim 1 , wherein the second antigen-binding region comprises VH and VL region sequences selected from the group consisting of:
a. SEQ ID NO: 59 and SEQ ID NO: 63, respectively,
b. SEQ ID NO: 66 and SEQ ID NO: 70, respectively,
c. SEQ ID NO: 72 and SEQ ID NO: 63 respectively,
d. SEQ ID NO: 75 and SEQ ID NO: 79, respectively, and
e. SEQ ID NO: 82 and SEQ ID NO: 86, respectively.
8. The composition according to claim 1 , wherein the first antigen binding region comprises a variable heavy chain (VH) VH region comprising the CDR sequences HCDR1, HCDR2 and HCDR3 and a variable light chain (VL) VL region comprising the CDR sequences LCDR1, LCDR2 and LCDR3 selected from the group consisting of:
a. SEQ ID NOs: 22, 23, and 24, respectively, and SEQ ID NO: 26, the sequence EAS, and SEQ ID NO: 27, respectively,
b. SEQ ID NOs: 29, 30, and 31, respectively, and SEQ ID NO: 33, the sequence AAS, and SEQ ID NO: 34 respectively,
c. SEQ ID NOs: 36, 37, and 38, respectively, and SEQ ID NO: 40, the sequence KAS, and SEQ ID NO: 41, respectively,
d. SEQ ID NOs: 43, 44, and 45, respectively, and SEQ ID NO: 47, the sequence YAS, and SEQ ID NO: 48 respectively,
e. SEQ ID NOs: 43, 44, and 45, respectively, and SEQ ID NO: 47, the sequence YAS, and SEQ ID NO: 58 respectively,
f. SEQ ID NOs: 8, 9, and 10, respectively, and SEQ ID NO: 12, the sequence VAT, and SEQ ID NO: 13 respectively, and
g. SEQ ID NOs: 15, 16, and 17, respectively, and SEQ ID NO: 19, the sequence FAK, and SEQ ID NO: 20, respectively, and
the second antigen-binding region comprises a VH region comprising the CDR sequences HCDR1, HCDR2 and HCDR3 and a VL region comprising the CDR sequences LCDR1, LCDR2 and LCDR3 selected from the group consisting of:
h. SEQ ID NOs: 60, 61, and 62, respectively, and SEQ ID NO: 64, the sequence DAS, and SEQ ID NO: 65, respectively,
i. SEQ ID NOs: 67, 68, and 69, respectively, and SEQ ID NO: 64, the sequence DAS, and SEQ ID NO: 71, respectively,
j. SEQ ID NOs: 73, 74, and 62, respectively, and SEQ ID NO: 64, the sequence DAS, and SEQ ID NO: 65, respectively,
k. SEQ ID NOs: 76, 77, and 78, respectively, and SEQ ID NO: 80, the sequence ATS, and SEQ ID NO: 81, respectively, and
l. SEQ ID NOs: 83, 84, and 85, respectively, and SEQ ID NO: 87, the sequence QMS, and SEQ ID NO: 88 respectively.
9. The composition according to claim 1 , wherein the first antigen binding region comprises the variable heavy chain (VI) VH and variable light chain (VL) VL region sequences selected from the group consisting of:
a. SEQ ID NO: 49 and SEQ ID NO: 50, respectively,
b. SEQ ID NO: 51 and SEQ ID NO: 52, respectively,
c. SEQ ID NO: 53 and SEQ ID NO: 54, respectively,
d. SEQ ID NO: 55 and SEQ ID NO: 56, respectively,
e. SEQ ID NO: 55 and SEQ ID NO: 57, respectively,
f. SEQ ID NO: 7 and SEQ ID NO: 11, respectively, and
g. SEQ ID NO: 14 and EQ SEQ ID NO: 18, respectively, and
the second antigen-binding region comprises the VH and VL region sequences selected from the group consisting of:
h. SEQ ID NO: 59 and SEQ ID NO: 63, respectively,
i. SEQ ID NO: 66 and SEQ ID NO: 70, respectively,
j. SEQ ID NO: 72 and SEQ ID NO: 63, respectively,
k. SEQ ID NO: 75 and SEQ ID NO: 79, respectively, and
l. SEQ ID NO: 82 and SEQ ID NO: 86, respectively.
10. The composition according to claim 1 , wherein the first and/or second antibody is human, humanized or chimeric.
11. The composition according to claim 1 , wherein the first antibody is humanized and the second antibody is human.
12. The composition according to claim 1 , wherein the first and/or second antibody is a monoclonal antibody.
13. The composition according to claim 1 , wherein the first and/or second antibody is a human IgG1, IgG2, IgG3 or IgG4 isotype.
14. The composition according to claim 1 , wherein the first and/or second antibody is an IgG1m (f), IgG1m (a), IgG1m (z), IgG1m (x) allotype or mixed allotype.
15. A method of inducing cell death, or inhibiting growth and/or proliferation of a tumor cell expressing CD37 and CD20, comprising administering to an individual in need thereof the composition according to claim 1 .
16. The method according to claim 15 , comprising administering a further therapeutic agent.
17. The method according to claim 16 , wherein the further therapeutic agent is selected from the group consisting of: doxorubicin, cisplatin, bleomycin, carmustine, cyclophosphamide, chlorambucil, bendamustine, vincristine, fludarabine, ibrutinib and venetoclax.
18. A method of treating an individual having a solid tumor and/or hematological tumor, comprising administering to said individual an effective amount of the composition according to claim 1 .